Mace has announced significant promotions within its contracting division.
- Rob Lemming is appointed Managing Director of Public Sector & Life Sciences.
- Alister Grey assumes the role of Managing Director for Technology & Manufacturing.
- The appointments emphasize Mace’s strategic focus on pharmaceuticals and data centres.
- This leadership shift aligns with Mace’s growth ambitions in emerging markets.
Mace has recently made notable leadership changes by promoting two key individuals to managing director positions within its contracting division. Rob Lemming has been elevated to Managing Director for Public Sector & Life Sciences, while Alister Grey takes on the role of Managing Director for Technology & Manufacturing. These appointments underscore the company’s strategic focus on expanding its footprint in the burgeoning markets of pharmaceuticals and data centres.
Rob Lemming, who joined Mace in 2014, has a commendable track record, notably working on the AstraZeneca Discovery Centre in Cambridge. He has played a pivotal role in strengthening Mace’s pipeline in the UK life sciences and pharmaceutical markets. His new role is expected to further bolster Mace’s involvement in ground-breaking research infrastructure, which is increasingly vital for societal advancement.
Conversely, Alister Grey joined Mace in 2016 and has been instrumental in developing Mace’s construction management delivery model, as evidenced by his work on the substantial £1.8bn second phase of Battersea Power Station in London. As Managing Director for Technology & Manufacturing, Grey will oversee the construction of data centres, crucial for supporting the ongoing technology revolution driven by advancements in AI.
Mace Construct Chief Executive Gareth Lewis highlighted the importance of these appointments, stating that the company’s ambitious global expansion and sector diversification require capable leaders. In Gareth’s words: “We have ambitious targets to expand our business across the globe and in diverse sectors, and to do this it is important that we have the right people in place.”
In response to his promotion, Alister Grey noted the essential nature of constructing digital infrastructure to support technological advancements, saying: “There is a technology revolution underway… we have led the way on the delivery of challenging projects like the construction of hyperscale data centres.” Rob Lemming echoed these sentiments, emphasising the significant capital investments by global pharmaceutical companies in new life science facilities, crucial for enabling future research.
These strategic leadership changes position Mace well to capitalise on opportunities within the pharmaceutical and data centre sectors.
